Stopping TNF inhibitors worth considering in stable RA

Stopping TNF inhibitors worth considering in stable RA PharmacoEconomics & Outcomes News 804, p32 - 2 Jun 2018 Stopping TNF inhibitors worth considering in stable RA Withdrawing tumour necrosis-factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) with low disease activity can save considerable costs while resulting in only a small loss of QALYs. This is the main finding of an economic evaluation that used data from the POET trial to assess the cost effectiveness of withdrawing TNF inhibitors in patients with RA with low disease activity. In the 1-year trial, patients with RA, who had been treated with TNF inhibitors for ≥ 1 year, were randomised to the Stop group (n = 531) or the Continuation group (286). The data analysis showed that mean drug costs were substantially lower in the Stop group (€4894 vs €12 450 per patient per year) but non-drug healthcare costs were higher (€2122 vs €1663 per patient per year; 2016 values). The mean cost savings in the Stop group were estimated at €7133 per year, and mean QALY loss at 0.022, compared with the Continuation group. The mean saved cost per QALY lost in the Stop group was estimated at €368 269. Withdrawal of TNF inhbitors had a 100% probability of being cost effective at a willingness-to-accept of €98 438 per QALY lost, while continuation of TNF inhbitors was not cost effective at a willingness-to-pay of €100 000 per QALY gained. * Potential Optimalisation of Expediency and Effectiveness of TNFis Tran-Duy A, et al. An Economic Evaluation of Stopping versus Continuing TNF- Inhibitor Treatment in Rheumatoid Arthritis Patients in Remission or Low Disease Activity: results from the POET randomized trial. Arthritis and Rheumatology : 9 May 2018. Available from: URL: http://doi.org/10.1002/art.40546 803322516 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Stopping TNF inhibitors worth considering in stable RA

Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/stopping-tnf-inhibitors-worth-considering-in-stable-ra-bXwyYlvUdl
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-018-4996-x
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 804, p32 - 2 Jun 2018 Stopping TNF inhibitors worth considering in stable RA Withdrawing tumour necrosis-factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) with low disease activity can save considerable costs while resulting in only a small loss of QALYs. This is the main finding of an economic evaluation that used data from the POET trial to assess the cost effectiveness of withdrawing TNF inhibitors in patients with RA with low disease activity. In the 1-year trial, patients with RA, who had been treated with TNF inhibitors for ≥ 1 year, were randomised to the Stop group (n = 531) or the Continuation group (286). The data analysis showed that mean drug costs were substantially lower in the Stop group (€4894 vs €12 450 per patient per year) but non-drug healthcare costs were higher (€2122 vs €1663 per patient per year; 2016 values). The mean cost savings in the Stop group were estimated at €7133 per year, and mean QALY loss at 0.022, compared with the Continuation group. The mean saved cost per QALY lost in the Stop group was estimated at €368 269. Withdrawal of TNF inhbitors had a 100% probability of being cost effective at a willingness-to-accept of €98 438 per QALY lost, while continuation of TNF inhbitors was not cost effective at a willingness-to-pay of €100 000 per QALY gained. * Potential Optimalisation of Expediency and Effectiveness of TNFis Tran-Duy A, et al. An Economic Evaluation of Stopping versus Continuing TNF- Inhibitor Treatment in Rheumatoid Arthritis Patients in Remission or Low Disease Activity: results from the POET randomized trial. Arthritis and Rheumatology : 9 May 2018. Available from: URL: http://doi.org/10.1002/art.40546 803322516 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off